| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4be2300a741a69aa1b8bb47a88899f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2014-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5679a75f399ac43ab86a1d51a52b69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015f184ac56318d8bdf787861e1c3d52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf61c8be64b05ae30498b3b01b0840f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad32ec58389fe0082a0834ee84a762d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_355519639235753bec2b3678bb4ff5e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_660b7b52bd50ed29c5c125b29e93bf32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f416942a8c44e07fbafb5e2c18a21a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e843cf5b682aa811ebfa4f8942298a7 |
| publicationDate |
2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20150087516-A |
| titleOfInvention |
Pharmaceutical composition for treating diabetes containing cell permeable SIRT2 fusion protein |
| abstract |
SIRT2 (Sirtuin 2) is one of a family of sirtuin proteins that undergo important cell survival functions under certain conditions. However, the biological function and mechanism of SIRT2 in diabetes is not well known. The purified SIRT2 fusion protein was permeabilized in time and dose dependent manner into RINm5F cells and protected against cell death and cytotoxicity induced by lipopolysaccharide and hydrogen peroxide. The SIRT2 fusion protein reduced the intracellular reactive oxygen species concentration . In addition, inhibition of glucose and insulin secretion was inhibited in streptozotocin - induced diabetic model animals. These results indicate that the SIRT2 fusion protein is useful as a therapeutic agent for diabetes. |
| priorityDate |
2014-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |